\documentclass[dvips,10pt]{article}
\usepackage{graphicx}
\setlength{\oddsidemargin}{-0.3in}
\setlength{\textwidth}{7.0in}
\setlength{\topmargin}{-0.70in}
\setlength{\textheight}{9.5in}
\pagestyle{myheadings}
\markright{ {\rm {
GLND DSMC Report - Recruitment and Baseline
 \hspace{2em}
Mon Aug 18 14:27:05 EDT 2008
\hfill
\hspace{3em}
}}}
\headsep=0.2in
\begin{document}
\vspace*{1in}
\begin{center}
{\Huge{CONFIDENTIAL}}
\end{center}
\vspace*{0.5in}
\begin{center}
{\Huge{GLND}}
\end{center}
\vspace*{0.5in}
\begin{center}
{\Huge{Data Safety Monitoring Board Report}}
\end{center}
\vspace*{0.25in}
\begin{center}
{\Huge{
Recruitment and Baseline
}}
\end{center}
\vspace*{1in}
\begin{center}
{\Huge{GLND DSMB Meeting}}
\end{center}
\begin{center}
{\Huge{
Mar 6, 2007
}}
\end{center}
\begin{center}
{\Huge{Atlanta, GA}}
\end{center}
\vspace*{1in}
\begin{center}
\noindent
{\Large{Includes patients enrolled and follow-up data received as of Feb 12, 2007}}
\end{center}
\vspace*{0.5in}
\begin{center}
{\Large{Report prepared  Mon Aug 18 14:27:05 EDT 2008 }}
\end{center}
\clearpage
\vspace*{1in}
\begin{center}
{\Huge{Table of Contents}}
\end{center}
\listoftables
\listoffigures
\clearpage
\begin{table}[t]
\caption
{ AE Unrelated to Glutamine. }
\begin{center}
\begin{tabular}{ @{}l@{}
@{}l@{}@{}p{1.5em}@{}@{}c@{}@{}p{1.5em}@{}@{}c@{}
}
\hline

& \parbox{6em}{\begin{center}Adverse Event\end{center}} && \parbox{6em}{\begin{center}Total n=62\end{center}} && \parbox{6em}{\begin{center}Days From Enrollment  (median)\end{center}} \\

\hline

\\
& Respiratory distress && 12( 12) 19.4\% && 5 \\
& Tracheostomy && 13( 13) 21.0\% && 8 \\
& Significant pulmunary aspiration && 0(  0)  0.0\% &&  \\
& Pneumothorax && 1(  1)  1.6\% && 13 \\
& Pulmonary emboli && 1(  1)  1.6\% && 26 \\
& Wound dehiscence && 2(  2)  3.2\% && 12 \\
& New onset significant hemorrhage && 6(  5)  8.1\% && 8 \\
& 
Mechanical intestinal obstr. && 0(  0)  0.0\% &&  \\
& Myocardial infarction && 2(  1)  1.6\% && 12 \\
& Cerebrovascular accident && 3(  3)  4.8\% && 1 \\
& Re-admission to ICU/SICU && 7(  7) 11.3\% && 21 \\
& New onset significant skin rash && 1(  1)  1.6\% && 3 \\
& 
Non-infectious pancreatitis && 0(  0)  0.0\% &&  \\
\\
\hline \\

\end{tabular}


\parbox{ 5in }{ \# AEs (\# Pat) \% Pat } \\
 \vspace{1em}\end{center}
 \end{table}
\begin{table}[t]
\caption
{ AE Potentially Related to Glutamine. }
\begin{center}
\begin{tabular}{ @{}l@{}
@{}l@{}@{}p{1.5em}@{}@{}c@{}@{}p{1.5em}@{}@{}c@{}
}
\hline

& \parbox{6em}{\begin{center}Adverse Event\end{center}} && \parbox{6em}{\begin{center}Total n= .\end{center}} && \parbox{6em}{\begin{center}Days From Enrollment  (median)\end{center}} \\

\hline

\\
& Worsening renal function && 4(  4)  6.5\% && 10 \\
& Worsening renal function && 1(  .)   . \% && 10 \\
& Worsening renal function && .(  .)   . \% && 10 \\
& Worsening renal function && .(  .)   . \% && 10 \\
& Worsening renal function && 3(  .)   . \% && 10 \\
& Worsening hepatic function && 1(  1)  1.6\% && 15 \\
& Worsening hepatic function && .(  .)   . \% && 15 \\
& Worsening hepatic function && .(  .)   . \% && 15 \\
& Worsening hepatic function && .(  .)   . \% && 15 \\
& Worsening hepatic function && 1(  .)   . \% && 15 \\
& Encephalopathy && 1(  1)  1.6\% && 2 \\
& Encephalopathy && .(  .)   . \% && 2 \\
& Encephalopathy && .(  .)   . \% && 2 \\
& Encephalopathy && 1(  .)   . \% && 2 \\
& Encephalopathy && .(  .)   . \% && 2 \\
& Hyperglycemia && 57( 24) 38.7\% && 11 \\
& Hyperglycemia && 21(  .)   . \% && 11 \\
& Hyperglycemia && 20(  .)   . \% && 11 \\
& Hyperglycemia && 6(  .)   . \% && 11 \\
& Hyperglycemia && 10(  .)   . \% && 11 \\
& Hypoglycemia && 2(  1)  1.6\% && 14 \\
& Hypoglycemia && .(  .)   . \% && 14 \\
& Hypoglycemia && .(  .)   . \% && 14 \\
& Hypoglycemia && 2(  .)   . \% && 14 \\
& Hypoglycemia && .(  .)   . \% && 14 \\
\\
\hline \\

\end{tabular}


\parbox{ 5in }{ \# AEs (\# Pat) \% Pat \newline Hypoglycemia information collected for the last 14 patients only \newline \newline All adverse events were indicated to be either Definitely not releated or Probably not related 
 to study drug } \\
 \vspace{1em}\end{center}
 \end{table}
\clearpage
\begin{table}[t]
\caption
{ AE Unrelated to Glutamine by Treatment. }
\begin{center}
\begin{tabular}{ @{}l@{}
@{}l@{}@{}p{1.5em}@{}@{}c@{}@{}p{1.5em}@{}@{}c@{}@{}p{1.5em}@{}@{}c@{}@{}p{1.5em}@{}@{}c@{}
}
\hline

& \parbox{6em}{\begin{center}Adverse Event\end{center}} && \parbox{6em}{\begin{center}Treatment A n=30\end{center}} && \parbox{6em}{\begin{center}Days From Enrollment A (median)\end{center}} && \parbox{6em}{\begin{center}Treatment B n=32\end{center}} && \parbox{6em}{\begin{center}Days From Enrollment B (median)\end{center}} \\

\hline

\\
& Respiratory distress && 7(  7) 23.3\% && 5 && 5(  5) 15.6\% && 2 \\
& Tracheostomy && 9(  9) 30.0\% && 8 && 4(  4) 12.5\% && 10 \\
& Significant pulmunary aspiration && 0(  0)  0.0\% &&  && 0(  0)  0.0\% &&  \\
& Pneumothorax && 1(  1)  3.3\% && 13 && 0(  0)  0.0\% &&  \\
& Pulmonary emboli && 1(  1)  3.3\% && 26 && 0(  0)  0.0\% &&  \\
& Wound dehiscence && 1(  1)  3.3\% && 5 && 1(  1)  3.1\% && 18 \\
& New onset significant hemorrhage && 3(  3) 10.0\% && 20 && 3(  2)  6.3\% && 6 \\
& 
Mechanical intestinal obstr. && 0(  0)  0.0\% &&  && 0(  0)  0.0\% &&  \\
& Myocardial infarction && 0(  0)  0.0\% &&  && 2(  1)  3.1\% && 12 \\
& Cerebrovascular accident && 2(  2)  6.7\% && 1 && 1(  1)  3.1\% && 9 \\
& Re-admission to ICU/SICU && 4(  4) 13.3\% && 18 && 3(  3)  9.4\% && 21 \\
& New onset significant skin rash && 1(  1)  3.3\% && 3 && 0(  0)  0.0\% &&  \\
& 
Non-infectious pancreatitis && 0(  0)  0.0\% &&  && 0(  0)  0.0\% &&  \\
\\
\hline \\

\end{tabular}


\parbox{ 5in }{ \# AEs (\# Pat) \% Pat } \\
 \vspace{1em}\end{center}
 \end{table}
\begin{table}[t]
\caption
{ AE Potentially Related to Glutamine by Treatment. }
\begin{center}
\begin{tabular}{ @{}l@{}
@{}l@{}@{}p{1.5em}@{}@{}c@{}@{}p{1.5em}@{}@{}c@{}@{}p{1.5em}@{}@{}c@{}@{}p{1.5em}@{}@{}c@{}
}
\hline

& \parbox{6em}{\begin{center}Adverse Event\end{center}} && \parbox{6em}{\begin{center}Treatment A n=30\end{center}} && \parbox{6em}{\begin{center}Days From Enrollment A (median)\end{center}} && \parbox{6em}{\begin{center}Treatment B n=32\end{center}} && \parbox{6em}{\begin{center}Days From Enrollment B (median)\end{center}} \\

\hline

\\
& Worsening renal function && 2(  2)  6.7\% && 12 && 2(  2)  6.3\% && 9 \\
& Worsening hepatic function && 0(  0)  0.0\% &&  && 0(  0)  0.0\% &&  \\
& Encephalopathy && 0(  0)  0.0\% &&  && 1(  1)  3.1\% && 2 \\
& Hyperglycemia && 24(  9) 30.0\% && 14 && 33( 15) 46.9\% && 7 \\
& Hypoglycemia && 2 (1/5) 20.0\% && 14 && 0(  0)  0.0\% &&  \\
\\
\hline \\

\end{tabular}


\parbox{ 5in }{ \# AEs (\# Pat) \% Pat \newline Hypoglycemia information collected for the last 14 patients only } \\
 \vspace{1em}\end{center}
 \end{table}
\clearpage
\end{document}
